- Conditions
- Hepatocellular Carcinoma
- Interventions
- MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day, MB07133 1800 mg/m2/day, MB07133 2400 mg/m2/day
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Orange, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 317
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
- Biological · Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Melphalan/HDS, Sorafenib
- Device · Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study, Sorafenib Tosylate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 659
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more
- Conditions
- Liver Neoplasms, Neoplasm Metastasis
- Interventions
- Isolated hepatic portal and arterial perfusion, Melphalan
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Radiation Segmentectomy
- Radiation
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Cancer
- Interventions
- T900607
- Drug
- Lead sponsor
- University Hospitals Seidman Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- escitalopram oxalate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
- Interventions
- Trametinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 8
- States / cities
- Sacramento, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Placebo, GC33
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Bethesda, Maryland • Detroit, Michigan + 4 more
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
- Interventions
- sodium thiosulfate, examination
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more
- Conditions
- Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic
- Interventions
- Liver Transplant
- Procedure
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Newark, New Jersey
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Interventions
- Cixutumumab, Laboratory Biomarker Analysis, Sorafenib Tosylate
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 6
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 2 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Pasadena, California • Gainesville, Florida • Louisville, Kentucky + 1 more
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IV Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
- Interventions
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Interventions
- cediranib maleate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Liver Cancer
- Interventions
- thalidomide, chemoembolization with doxorubicin/collagen
- Drug · Procedure
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Cancer
- Interventions
- biologic sample preservation procedure, medical chart review, Patient interview
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Y-90 TARE, Atezolizumab, Bevacizumab
- Other · Drug
- Lead sponsor
- Aiwu Ruth He, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Genetic
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 5
- States / cities
- La Jolla, California • Rochester, Minnesota • Billings, Montana + 2 more
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- Liver Cancer, Metastatic Cancer
- Interventions
- Radiofrequency Ablation
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma, Liver Cancer
- Interventions
- PHY906, capecitabine
- Drug
- Lead sponsor
- PhytoCeutica
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 4
- States / cities
- Duarte, California • Stanford, California • New Haven, Connecticut + 1 more
- Conditions
- Liver Cancer
- Interventions
- bevacizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California